**Appendix Table E42. Results from the single study assessing the ability of VerifyNow to predict platelet reactivity during followup (continuous measurement) in patients with ischemic heart disease**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, year**  **UID**  **Country**  **Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Reactivity Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **No. with given phenotype** | **Platelet reactivity measurement for the phenotype group**  **[metric]** | **SD/SE (report value and metric)** | **Statistical method** | **Mean difference (state if other metric)** | **95% CI of mean difference (state if other metric)** | **P (between which groups?)**  **[statistical test]** | **Adjusted?**  **[YES/NO/NR]**  **If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| Cotton, 2010{Cotton, 2010 75 /id}  20406238  UK  NR | 300 mg or 600 mg LD Clopidogrel and maintaining 75 mg+ Aspirin | VerifyNow | PRU | PRU mean AUC15 | NR | PRU≤240 | 19 | Mean 493 | SD 238 | t-test | NR | NR | 0.0001 comparing the lower group | NR | NR |  |
|  |  |  |  |  |  | PRU>240 | 29 | Mean 911 | SD195 |  |  |  |  |  |  |  |